期刊文献+

非洛贝特纳米混悬剂的制备及其体外溶出性考察 被引量:4

Preparation of Fenofibrate Nanosuspension and in Vitro Dissolution Study
原文传递
导出
摘要 目的:制备非洛贝特纳米混悬剂,以促进药物溶出。方法:以非洛贝特为主药,采用熔融乳化法联合高压均质法制备纳米混悬剂;选取处方中表面活性剂泊洛沙姆188(Poloxamer188)与聚乙烯吡咯烷酮(PVP)K30用量比、均质压力、均质次数为考察因素,药物粒径为指标设计正交试验筛选制备工艺,并进行验证试验;同时考察制剂溶出速率和溶出浓度。结果:最佳制备工艺为Poloxamer188:PVPK30用量比2:1、均质压力800bar,均质次数为9。所制纳米粒平均粒径为356nm,多分散系数为0.19,平均Zeta电位为-39mV。制剂5min时溶出浓度可达20.10mg·L-1,4h时达25.46mg·L-1,接近完全溶出。结论:将难溶药物非诺贝特制成纳米混悬剂可以显著改善其溶出作用。 OBJECTIVE: To prepare Fenofibrate nanosuspension so as to improve the dissolution of it. METHODS: Fenofibrate nanosuspension was prepared by melting-emulsifcation method combined with high pressure homogenization using fenofibrate as main component. The preparation technology was optimized by orthogonal test with ratio of the amount of Poloxamer 188 to that of PVP K30, homogenization pressure and homogenization time as factors and with particle size as index. The optimized technology was verified. The dissolution rate and dissolved concentration of preparation were investigated. RESULTS: The optimized technology was as follows: the ratio of amount of Poloxamer 188 to PVP K30 was 2: 1; homogenization pressure of 800 bar and homogenization time of 9 times. Mean particle size of prepared nanoparticle was 356 nm and polydispersity index was 0.19 with average Zeta potential of --39 mV. The dissolved concentration of preparation was 20.10 mg·L^-1 at 5 min and 25.46 mg·L^-1 at 4 h. Prepared nanoparticle had nearly dissolved completely. CONCLUSION: Fenofibrate nanosuspension can effectively increase solubility of fenofibrate.
出处 《中国药房》 CAS CSCD 北大核心 2010年第45期4268-4271,共4页 China Pharmacy
基金 江苏省高校自然科学基金资助项目(09JKB350001) 南京工业大学学科基金资助项目(39728007)
关键词 正交设计 非诺贝特 纳米混悬剂 制备工艺 溶出浓度 Orthogonal test Fenofibrate Nanosuspension Preparation technology Dissolved concentration
  • 相关文献

参考文献5

  • 1Adkins JC, Faulds D. Micronized fenofibrate. A review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidemia[J]. Drugs, 1997,54 (4) : 615.
  • 2Elaine ML. Nanocrystals : Resolving Pharmaceutical Formulation lssues Associated with Poorly Water-soluble Compounds[M]. Orlando Florida: Marcel Dekker Press, 2002 : 45.
  • 3Elaine ML, Gary GL, Eugene RC. Nanosizing: a formulation approach for poorly-water-soluble compounds[J]. European Journal of Pharmaceutical Sciences, 2003, 2 (18):113.
  • 4李学明,顾立,王永禄,吴茂东,陈国广.熔融乳化法制备非诺贝特纳米混悬剂[J].中国医药工业杂志,2009,40(5):349-354. 被引量:9
  • 5Grenier P, Vergnault G, Nhamias A. Nanoparticulateformulations of fenofibrate[P]. USA: 20050095297.2005- 05-05.

二级参考文献13

  • 1李满,满世伟,金丽丹.非诺贝特降脂特点简介[J].实用药物与临床,2005,8(S1):35-36. 被引量:7
  • 2朱建芬,吴祥根.纳米混悬剂的制备方法及在药剂学中应用的研究进展[J].中国医药工业杂志,2006,37(3):196-200. 被引量:38
  • 3钱帅,张建军,高缘,周建平.纳米混悬剂研究进展[J].药学进展,2007,31(1):9-14. 被引量:16
  • 4Vogt M, Kunath K, Dressman JB. Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: comparison with commercial preparations [J]. Eur J Pharm Biopharm, 2008, 68 (2) : 283-288.
  • 5Keck CM, Muller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation [J]. Eur J Pharm Biopharm, 2006, 62 (1) : 3-16.
  • 6She ZY, Ke X, Ping QN, et al. Preparation of breviscapine nanosuspension and its pharmacokinetic behavior in rats [J]. Chin J Nat Med Jan, 2007, 5 (1) : 50-55.
  • 7Kocbek P, Baumgartner S, Kristl J. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs [J]. Int J Pharm, 2006, 312(1-2): 179-186.
  • 8Hecq J, Deleers M, Fanara D, et al. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine [J]. Int J Pharm, 2005, 299(1-2) : 167-177.
  • 9施洁明 何仲贵 孙淑英.非诺贝特体外溶出度考察及其微粉化制剂的研究.沈阳药科大学学报,2003,20(5):317-320.
  • 10Hanafy A, Spahn-Langguth H, Vergnault G, et al. Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug [J]. Adv Drug Deliv Rev, 2007, 59 (6):419-426.

共引文献8

同被引文献53

  • 1冀艳艳,韩国华,朱澄云.改善口服难溶性药物生物利用度的方法[J].中国药剂学杂志(网络版),2012(5):86-92. 被引量:14
  • 2夏路风,刘蕾,傅得兴.新型广谱三唑类抗真菌药泊沙康唑[J].中国新药杂志,2007,16(15):1226-1231. 被引量:8
  • 3Gao L,Liu GY,Ma JL,et al.Application of drug nanocrystal technologies on oral drug delivery of poorly soluble drugs[J].Pharm Res,2013,30(2):307.
  • 4Pádua TA,de Abreu BS,Costa TE,et al.Anti-inflammatory effects of methyl ursolate obtained from a chemically derived crude extract of apple peels:potential use in rheumatoid arthritis[J].Arch Pharm Res,2014,37(11):1 487.
  • 5Lee YJ,Lee YM,Lee CK,et al.Therapeutic applications of compounds in the Magnolia family[J].Pharmacol Ther,2011,130(2):157.
  • 6Song JS,Lim KM,Kang S,et al.Procoagulant and prothrombotic effects of the herbal medicine,dipsacus asper and its active ingredient,dipsacus saponin C,on human platelets[J].J Thromb Haemost,2012,10(5):895.
  • 7Chavhan SS,Petkar KC,Sawant KK.Nanosuspensions in drug delivery:recent advances,patent scenarios,and commercialization aspects[J].Crit Rev Ther Drug Carrier Syst,2011,28(5):447.
  • 8Danhier F,Ucakar B,Vanderhaegen ML,et al.Nanosuspension for the delivery of a poorly soluble anti-cancer kinase inhibitor[J].Eur J Pharm Biopharm,2014,88(1):252.
  • 9Jethara SI,Patel AD,Patel MR,et al.Recent survey on nanosuspension:a patent overview[J].Recent Pat Drug Deliv Formul,2015,9(1):65.
  • 10Müller RH,Gohla S,Keck CM.State of the art of nanocrystals-special features,production,nanotoxicology aspects and intracellular delivery[J].Eur J Pharm Biopharm,2011,78(1):1.

引证文献4

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部